Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to nutlin-3 mediated apoptosis

Cell Cycle

Volumn 9, Issue 7, 2010, Pages 1373-1379

  Cipriano, Rocky ^a   Patton, John T ^a   Mayo, Lindsey D ^c   Jackson, Mark W ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

BCL 2; Nutlin 3; p53; p73; PTEN

Indexed keywords

CASPASE; NUTLIN 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN P73;

APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; PHENOTYPE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

EID: 77953554440     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.7.11193     Document Type: Article

References (16)

1. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on tp53 mutation patterns and tumor phenotype: lessons from recent developments in the iarc tp53 database. Hum Mutat 2007; 28:622-9.
2. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73.
3. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of mdm2. Science 2004; 303:844-8.
4. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. Mdmx overexpression prevents p53 activation by the mdm2 inhibitor nutlin. J Biol Chem 2006; 281:33030-5.
5. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of hdmx expression dictate the sensitivity of normal and transformed cells to nutlin-3. Cancer Res 2006; 66:3169-76.
6. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006; 281:33036-44.
7. Seger YR, Garcia-Cao M, Piccinin S, Cunsolo CL, Doglioni C, Blasco MA, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002; 2:401-13.
8. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/akt pathway promotes translocation of mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598-603.
9. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. Pten tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3:117-30.
10. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by pten. Mol Cell 2006; 23:575-87.
11. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to dna damage. Nature 2002; 416:560-4.
12. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to nutlin-3 in cyclin d1 transformed cells occurs independently of p21. Cancer Res 2007; 67:9862-8.
13. Vaseva AV, Marchenko ND, Moll UM. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 2009; 8:1711-9.
14. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates bak and causes disruption of a bak-mcl1 complex. Nat Cell Biol 2004; 6:443-50.
15. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated mdm2 boosts the apoptotic activity of p53-mdm2 binding inhibitors by facilitating mdmx degradation. Cell Cycle 2008; 7:1604-12.
16. Jackson MW, Agarwal MK, Yang J, Bruss P, Uchiumi T, Agarwal ML, et al. p130/p107/p105rb-dependent transcriptional repression during dna-damage-induced cell cycle exit at g2. J Cell Sci 2005; 118:1821-32.